Legal & General Group Plc grew its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 36.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,013 shares of the biopharmaceutical company’s stock after purchasing an additional 4,512 shares during the quarter. Legal & General Group Plc’s holdings in Dynavax Technologies were worth $365,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of DVAX. Russell Investments Group Ltd. boosted its stake in shares of Dynavax Technologies by 24.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock valued at $1,496,000 after purchasing an additional 30,036 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Dynavax Technologies by 77.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 181,161 shares of the biopharmaceutical company’s stock worth $1,749,000 after acquiring an additional 79,141 shares in the last quarter. Rhumbline Advisers boosted its stake in Dynavax Technologies by 35.5% during the second quarter. Rhumbline Advisers now owns 60,503 shares of the biopharmaceutical company’s stock worth $584,000 after acquiring an additional 15,865 shares in the last quarter. State of Wisconsin Investment Board bought a new position in Dynavax Technologies during the second quarter worth $328,000. Finally, Bank of New York Mellon Corp boosted its stake in Dynavax Technologies by 41.7% during the second quarter. Bank of New York Mellon Corp now owns 250,862 shares of the biopharmaceutical company’s stock worth $2,421,000 after acquiring an additional 73,866 shares in the last quarter. 70.54% of the stock is currently owned by institutional investors.

Dynavax Technologies Co. (DVAX) opened at $18.50 on Friday. Dynavax Technologies Co. has a 1-year low of $3.70 and a 1-year high of $24.45. The firm has a market cap of $1,120.00, a price-to-earnings ratio of -9.44 and a beta of 1.31.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the prior year, the company posted ($0.90) earnings per share. The business’s revenue was down 68.8% on a year-over-year basis. equities research analysts forecast that Dynavax Technologies Co. will post -1.72 earnings per share for the current fiscal year.

In other Dynavax Technologies news, VP David Louis Johnson sold 3,092 shares of the company’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total transaction of $57,511.20. Following the transaction, the vice president now owns 7,780 shares in the company, valued at $144,708. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Robert Coffman sold 7,500 shares of the company’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total transaction of $141,750.00. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.

Several brokerages recently issued reports on DVAX. BidaskClub lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. ValuEngine lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Cantor Fitzgerald increased their target price on shares of Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Thursday, November 9th. Cowen reissued a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a research note on Friday, November 3rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $28.00 target price (up from $26.00) on shares of Dynavax Technologies in a research note on Monday, September 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. Dynavax Technologies presently has an average rating of “Buy” and a consensus price target of $25.17.

TRADEMARK VIOLATION WARNING: “Legal & General Group Plc Has $365,000 Stake in Dynavax Technologies Co. (DVAX)” was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/legal-general-group-plc-has-365000-stake-in-dynavax-technologies-co-dvax/1796894.html.

Dynavax Technologies Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.